Get Vaccinated Against the Covid Delta Variant

In summary: Delta variant, a Coronavirus strain first detected in India, is now officially designated as a variant of concern by the Centers for Disease Control and Prevention (CDC). This designation is given to variants shown to be more transmissible than the original strain, which can cause more severe disease and potentially reduce the effectiveness of treatments or vaccines. As a result, the CDC is urging people who have not yet been vaccinated against COVID-19 to do so now. The Delta variant looks like it might be up to 60 percent more infectious than other variants of COVID-19, and as a result, the CDC is concerned that it could lead to more widespread and severe infections. However, both vaccine versions currently available are still effective against Delta-infect
  • #316
I should be very easy to design new vaccines to target the new variants (e.g. the first mRNA vaccine prototypes were designed days after the SARS-CoV-2 genetic sequence was made public). Indeed, both Pfizer and Moderna started trials to measure the effectiveness of a booster against the Beta variant (which shows some difficulty with developing boosters to the variants -- the circulating variants can change before clinical trials finish). Recently, Pfizer has begun trials for a booster against the Delta variant.

However, there may be some scientific and social issues related to developing new boosters against the variants:
To counteract the impact of viral variants, one suggestion is to develop new vaccines that more closely reflect the circulating viruses. For example, Moderna has developed a novel vaccine targeting the B.1.1.7 VOC, which has been tested in preclinical trials57 and is now in clinical trials (NCT04785144). However, it is not clear how beneficial such vaccines designed specifically to target new variants will be. The main consideration will be how far the circulating viruses in autumn 2021 (when booster vaccination has been proposed in some countries) will have drifted antigenically from the original reference sequence of the SARS-CoV-2 S protein used for the first-generation vaccines. Although studies relating to the VOCs have shown reduced neutralization in vitro, there has been no significant reported impact on vaccine effectiveness, which suggests that the viral mutations predominantly increase transmissibility, but not necessarily immune escape. As the current vaccines still offer good protection against severe disease, there may be limited return on a new variant booster. Indeed, there may actually be negative unintended consequences. The first is that producing a new booster vaccine for the countries with sufficient income to afford substantial coverage with the first-generation vaccines may reduce manufacturing capacity for doses for lower-income countries. Second, boosting with a similar antigen may boost the antibody response to the original strain rather than prime for antibodies specific to the new strain58. This idea of ‘original antigenic sin’ refers to the boosting of responses to previously seen epitopes to the detriment of responses to new epitopes, particularly when they are closely related. Such a phenomenon has been observed for influenza, with individuals who were recently immunized with seasonal influenza vaccine producing lower antibody responses to 2009 pandemic influenza than previously unimmunized individuals59. Furthermore, the variants may be drifting apart, and so priming with a variant might narrow rather than broaden protection. It is our opinion that engineering novel booster vaccines should not be a priority at this time.

Whereas engineering new variant vaccines may not be beneficial, an alternative strategy is to boost immunity with a third dose of vaccine targeting the initial reference strain
https://www.nature.com/articles/s41577-021-00592-1
 
  • Like
Likes Sagittarius A-Star, Astronuc and atyy
Biology news on Phys.org
  • #317
"alternative strategy is to boost immunity with a third dose of vaccine targeting the initial reference strain"
This seems be what Israel has decided to do.

In Israel, Being Fully Vaccinated Now Means Three Shots

Holders of Israel’s vaccine passports must get a third dose of the Pfizer -BioNTech vaccine within six months of their second dose, or lose the so-called green pass that allows them more freedom.

“We are updating what it means to be vaccinated,” said Israel’s Coronavirus czar, Salman Zarka, at a press conference Sunday unveiling the new policy.

A study released by the Israeli health ministry on Sunday found that within 12 days, recipients of a third shot were 10 times less likely to become severely ill and 11 times less likely to become infected than people who had received their second dose five months earlier.

Israeli health officials say they don’t know whether additional boosters, beyond the third dose, will be needed. But they are moving aggressively to get as many people as possible vaccinated with a third shot, as the more contagious Delta variant of the virus spreads. All Israelis over the age of 12 are now eligible to receive a booster if five months have passed since their second shot.
 
  • Like
Likes Sagittarius A-Star and atyy
  • #318
Here's a Twitter thread from the Milo Lab with a link to the preprint "BNT162b2 vaccine booster dose protection: A nationwide study from Israel" mentioned by @nsaspook. "TL;DR: the booster dose improves protection against confirmed infection and severe disease by a factor of ≈10"
 
  • Like
Likes Sagittarius A-Star and Astronuc
  • #319
Ygggdrasil said:
However, there may be some scientific and social issues related to developing new boosters against the variants:

https://www.nature.com/articles/s41577-021-00592-1

They provide no evidence for:
Furthermore, the variants may be drifting apart, and so priming with a variant might narrow rather than broaden protection.
...
Whereas engineering new variant vaccines may not be beneficial, an alternative strategy is to boost immunity with a third dose of vaccine targeting the initial reference strain.
 
  • #320
Seems like there are new studies with regards to mixing of vaccines.

https://www.nature.com/articles/d41586-021-01359-3
https://www.nytimes.com/2021/06/24/world/europe/covid-vaccine-mix-and-match-pfizer-moderna.html

here is an article on boosters
https://www.nature.com/articles/d41586-021-02158-6

I do wonder myself , what could be potential adverse effects if indeed it is decided that at least for some age groups or professions they need to continually use a booster every 6 months or year.
Could it be that for more frequent use of the same vaccine the chances of additional side effects increase in frequency?
 
  • Like
  • Informative
Likes atyy and Sagittarius A-Star
  • #321
Sagittarius A-Star said:
They provide no evidence for:
Furthermore, the variants may be drifting apart, and so priming with a variant might narrow rather than broaden protection.
The idea that priming with a variant might narrow rather than broaden protection is based on the concept of "original antigenic sin" (OAS). The idea is that when boosting with a variant the immune system will preferentially activate memory B cells (which produce antibodies against the original antigen) rather than activate a set of new B cells (which could produce a set of new, more effective antibodies that better target the variant). The authors cite another published article discussing OAS in the context of COVID-19 boosters further:

“Original antigenic sin”: A potential threat beyond the development of booster vaccination against novel SARS-CoV-2 variants
https://www.cambridge.org/core/jour...ov2-variants/C8F4B9BE9E77EB566C71E98553579506

We have also discusses OAS in the context of COVID-19 in a previous thread: https://www.physicsforums.com/threa...o-endemic-coronaviruses.1005206/#post-6523013

The authors also point an example of OAS with previous influenza vaccines:

Reduced Antibody Responses to the Pandemic (H1N1) 2009 Vaccine after Recent Seasonal Influenza Vaccination
https://journals.asm.org/doi/10.1128/CVI.05053-11

[edit: here's a nice popular press article on OAS: https://www.statnews.com/2021/04/16...etter-some-experts-worry-they-could-be-worse/]
Whereas engineering new variant vaccines may not be beneficial, an alternative strategy is to boost immunity with a third dose of vaccine targeting the initial reference strain.
While the authors don't cite any data for this point, there are data to support this idea. See, for example, the pre-print from the study in Israel cited by @atyy https://www.physicsforums.com/threads/covid-delta-variant.1004265/post-6535265

Pfizer and Moderna have also submitted data on booster doses for the FDA to review, which should be publicly available soon.
 
Last edited:
  • Informative
  • Like
Likes Astronuc, atyy, jim mcnamara and 2 others
  • #322
artis said:
It's been known for a while that using two different types of vaccines that target the same antigen (a heterologous prime-boost strategy) is often better than two doses of the same type of vaccine (e.g. see this article from 2009 on the topic), so I'm glad people are exploring the strategy with the COVID-19 vaccines.

artis said:
I do wonder myself , what could be potential adverse effects if indeed it is decided that at least for some age groups or professions they need to continually use a booster every 6 months or year.
Could it be that for more frequent use of the same vaccine the chances of additional side effects increase in frequency?
Would this be much different than an annual flu vaccine? Can you cite any evidence or data to support the idea that frequent use of the same vaccine could lead to additional side effects? Remember, than the FDA requires clinical trials of the booster shots and reviews the data to look for evidence of problems like these. As stated above, the FDA will meet to review data on the Pfizer and Moderna boosters this month, so these safety and efficacy data will be made available to the public then. Furthermore, the CDC also closely monitors adverse effects from vaccines even after they have been authorized or approved in order to catch any unexpected adverse events (which is how they have observed rare one in 100,000 or one in one million adverse events linked to some of the vaccines, such as VITT).
 
Last edited:
  • Like
Likes PeroK
  • #323
Ygggdrasil said:
While the authors don't cite any data for this point, there are data to support this idea. See, for example, the pre-print from the study in Israel cited by @atyy https://www.physicsforums.com/threads/covid-delta-variant.1004265/post-6535265

Pfizer and Moderna have also submitted data on booster doses for the FDA to review, which should be publicly available soon.

Maybe we will see this year from clinical studies, which kind of antibodies (old or new) will be created, if 2 doses of Pfizer/BioNTech vaccine are followed by the updated version containing Delta mRNA.
While Pfizer and BioNTech believe a third dose of BNT162b2 has the potential to preserve the highest levels of protective efficacy against all currently tested variants including Delta, the companies are remaining vigilant and are developing an updated version of the Pfizer-BioNTech COVID-19 vaccine that targets the full spike protein of the Delta variant. The first batch of the mRNA for the trial has already been manufactured at BioNTech’s facility in Mainz, Germany. The Companies anticipate the clinical studies to begin in August, subject to regulatory approvals.
Source:
https://investors.biontech.de/news-...h-provide-update-booster-program-light-delta/
 
  • #324
Sagittarius A-Star said:
Maybe we will see this year from clinical studies, which kind of antibodies (old or new) will be created, if 2 doses of Pfizer/BioNTech vaccine are followed by the updated version containing Delta mRNA.

Source:
https://investors.biontech.de/news-...h-provide-update-booster-program-light-delta/
We might not have to wait that long. Back in March, Moderna and the NIH initiated a clinical trial to test variant-specific boosters (using a booster targeted against the Beta variant):

Approximately 60 volunteers who previously received mRNA-1273 as a participant in NIAID’s Phase 1 trial of mRNA-1273 (which began in March 2020) will enroll in the new variant Phase 1 trial. Approximately one year ago, these volunteers received two vaccinations of mRNA-1273 28 days apart at varying doses: 50 mcg, 100 mcg or 250 mcg. As part of the variant vaccine trial, these volunteers will be randomized to receive either a single booster vaccination of 50 mcg of mRNA-1273.351 (group 1A) or a single vaccination containing one 25-mcg dose of mRNA-1273 and one 25-mcg dose of mRNA-1273.351 (group 1B). The remaining participants from the March 2020 trial will be offered a booster shot of mRNA-1273 as part of a separate clinical trial protocol (for more information see clincialtrials.gov: NCT04283461).
https://www.nih.gov/news-events/new...ating-moderna-covid-19-variant-vaccine-begins

That clinical trial might have data relevant to whether OAS occurs with the COVID vaccines. Unfortunately, according to the ClinicalTrials.gov site, the trial does not have any results posted yet: https://clinicaltrials.gov/ct2/show/study/NCT04785144
 
  • Informative
Likes Sagittarius A-Star
  • #325

Children's Hospitals Are Pleading For Federal Help As They Run Out Of Beds​

https://www.npr.org/sections/corona...itals-coronavirus-covid-capacity-federal-help
A group of more than 220 children's hospitals is imploring the Biden administration for help, as a surge of young COVID-19 patients puts an "unprecedented strain" on their facilities and staff across the country.

Pediatric hospitals are "at or near capacity" and they expect to see more child patients as the school year resumes, according to the Children's Hospital Association.

"[T]here may not be sufficient bed capacity or expert staff to care for children and families in need," wrote association CEO Mark Wietecha in a letter to President Biden on Aug. 26.
I am baffled by persons who find it acceptable to exposure children and the general public to a virulent and potentially fatal respiratory virus.
 
  • #326
Well, we know that high levels of antibodies provide good protection against infection against all variants, the two issues to consider is actually achieving the high levels and then maintaining them. The antibody response is highly variable, but we can at least identify some people that are least likely to mount a good response and we now know that the 3 week gap between the 1 & 2nd dose isn't optimal, a longer gap gives a better response. We can also potentially mix vaccines, which provide a wider range of epitomes for the immune system to target, trials in the UK giving the AZ vaccine followed by the Pfizer, suggested it provided better and more enduring protection.

Regardless of these tweaks the fact is that protection from antibodies is a partial and temporary answer, as things stand variant specific vaccines seem to offer little advantage, we would be committed to continually developing and then administering boosters. Each of these carrying their own, albeit small risk, while offering significant enhanced protection for around 7 months of the year. It makes sense, as things stand in the management of the disease, to offer a 3rd vaccination to people at risk, while hoping for more effective treatments, even the WHO support that, despite the global supply problems.
However, the data coming out of Israel and the UK, and remember the UK has dropped all the mitigation requirements, we see a marked increase in infections, which is now at levels seen in the previous peaks, hospitalisations are also increasing, but are at a level less than a third of what it was with this number of infections and with the unvaccinated being disproportionally effected and deaths remaining low.

There have been some recent indications from the UK government, that while people who are considered highly vulnerable will be offered a further booster, the current level of protection in the population is probably as good as it gets. The view appears to be that this disease will be with us for some time and everyone will be exposed, probably repeatedly. The vaccine does offer considerable protection against severe disease and death but not against infection. This implies that vaccine refusal might represent less of a risk to the wider population, it is in fact this group that are already suffering disproportionally. It will be interesting as economies try to recover, to see if the funding to promote vaccination will continue to be made available.
So long as the level of deaths remain low, repeated exposure to the virus, will provide the periodic boosters, perhaps until newer interventions become available.
 
  • Like
Likes BillTre and atyy
  • #327
Ygggdrasil said:
That clinical trial might have data relevant to whether OAS occurs with the COVID vaccines. Unfortunately, according to the ClinicalTrials.gov site, the trial does not have any results posted yet: https://clinicaltrials.gov/ct2/show/study/NCT04785144

AstraZeneca has developed a new version of their vaccine containing minor genetic alterations to the spike protein based on the Beta (B.1.351, South African) variant. They claim, that they found no evidence for OAS in animal studies.
AstraZeneca said:
27 June 2021 13:00 BST
...
The first participants in a Phase II/III trial for the new COVID-19 variant vaccine AZD2816 were vaccinated today to assess its safety and immunogenicity in both previously vaccinated and unvaccinated adults.
The trial will recruit approximately 2,250 participants across UK, South Africa, Brazil and Poland.
...
AZD2816 has been built using the same adenoviral vector platform as with Vaxzevria, with minor genetic alterations to the spike protein based on the Beta (B.1.351, South African) variant. The Beta variant vaccine contains ten changes across the spike protein, many of which are also seen in other variants of concern ...
Source:
https://www.astrazeneca.com/media-c...ase-ii-iii-trial-participants-vaccinated.html

paper about animal study said:
We demonstrate AZD2816 is immunogenic after a single dose and when used as a booster dose in animals primed with original vaccine AZD1222, we see no evidence of original antigenic sin but high titre antibodies against a number of variant spike proteins. In addition, neutralisation titres against B.1.351 (Beta), B.1.617.1 (Kappa) and B.1.617.2 (Delta), are induced in these boost regimens. These data support the ongoing clinical development and testing of this new variant vaccine.
...
AZD2816 as a third dose can further enhance antibody responses induced by two doses of AZD1222
...
Overall the data shows that a booster dose with a new ChAdOx1 against the new variant B.1.351 (AZD2816), can further enhance antibody responses against SARS-CoV-2 B.1.351 and provide cross-reactivity against other variant proteins.
Source:
https://www.biorxiv.org/content/10.1101/2021.06.08.447308v1

In table 1, they compare AZD1222 + AZD1222 + AZD2816 to AZD1222 + AZD1222, but unfortunately not to AZD1222 + AZD1222 + AZD1222 (boost with original vaccine). That might have given evidence for or against OAS.
 
Last edited:
  • Like
Likes atyy, jim mcnamara and Ygggdrasil
  • #328
Ygggdrasil said:
However, there may be some scientific and social issues related to developing new boosters against the variants:
Furthermore, the variants may be drifting apart, and so priming with a variant might narrow rather than broaden protection. It is our opinion that engineering novel booster vaccines should not be a priority at this time.

Whereas engineering new variant vaccines may not be beneficial, an alternative strategy is to boost immunity with a third dose of vaccine targeting the initial reference strain
As long as there is sufficient cross-immunity between variants, it's indeed not a big problem in these transitive times. On long term, however a likely outcome is that there will be several competing main strains established, with very limited cross-immunity between them. That time not just 'variant' but likely multivalent boosters will be needed.
 
  • Informative
Likes bhobba
  • #329
Sagittarius A-Star said:
AstraZeneca has developed a new version of their vaccine containing minor genetic alterations to the spike protein based on the Beta (B.1.351, South African) variant.

They will also test boosting an mRNA vaccination with AZD1222 vs. AZD2816. That may give evidence for or against OAS.
mRNA booster: one dose of AZD1222
Previously vaccinated with an mRNA vaccine, dosing on day 1

mRNA booster: one dose of AZD2816
Previously vaccinated with an mRNA vaccine, dosing on day 1
Source:
https://clinicaltrials.gov/ct2/show/NCT04973449
 
  • #330
artis said:
https://www.worldometers.info/coronavirus/

Looking at the upper general statistical graphs of both daily new cases and daily deaths it seems that the third wave that is happening now is less severe in terms of deaths and also somewhat smaller compared to daily new cases,

Oh yes. While vaccine efficacy is interesting and important, the most important statistic is hospitalisation and death prevention. While efficacy is waning with both AZ and Pfizer, protection against hospitalisation and death remains very high.

Interestingly a recent study in Bahrain showed, as far as preventing death is concerned, there was some evidence of all the vaccines they tried the much-maligned in Australia, AZ vaccine, was the most effective:
https://economynext.com/vaccines-wo...-got-sinopharm-vs-pfizer-bahrain-study-85458/

I dearly would like to see the journal preprint, but it just goes to show this pandemic is constantly throwing up surprises.

Thanks
Bill
 
  • Like
Likes BillTre
  • #331
The rate of children and teens hospitalized because of the Coronavirus increased nearly five times in mid-August—and 10 times, for children under four—the Centers for Disease Control and Prevention (CDC) reported in two key studies released Friday, which also showed the worst rates of children struggling with the disease happening in the states with lower vaccination rates.
https://www.forbes.com/sites/kimber...y-almost-5-times-cdc-reports/?sh=125ddc501b30
The rate of children with Coronavirus who end up hospitalized is 49.7 per 100,000 children as of August 14, with the highest rate of hospitalizations among kids under the age of 4 (69%) followed by teens between the ages of 12-17 (64%).

Hospitalizations began to climb due to the spread of the delta variant in mid-August, when many students returned to school, and children and teen hospitalizations increased nearly five times mid-August compared to the end of July, while hospitalizations for children under the age of 4 increased 10 times during the same period.
The new studies follow a record-breaking month for U.S. children hospitalizations, with 330 children admitted daily between August 20 and August 26, according to the CDC. The rise in hospitalizations coincide with the return to school for many students along with the rising spread of the delta variant in all states throughout the U.S.
 
  • #332
bhobba said:
Interestingly a recent study in Bahrain showed, as far as preventing death is concerned, there was some evidence of all the vaccines they tried the much-maligned in Australia, AZ vaccine, was the most effective:
https://economynext.com/vaccines-wo...-got-sinopharm-vs-pfizer-bahrain-study-85458/

I dearly would like to see the journal preprint, but it just goes to show this pandemic is constantly throwing up surprises.
https://www.researchsquare.com/article/rs-828021/v1
Morbidity and mortality from COVID-19 post-vaccination breakthrough infections in association with vaccines and the emergence of variants in Bahrain
Manaf AlQahtani, Sujoy Bhattacharyya, Abdulla Alawadi, Hamad Al Mahmeed, Jaleela Al Sayed, Jessica Justman, Wafaa M. El-Sadr, Jack Hidary, Siddhartha Mukherjee

Their data are not purely Delta, but contain a lot of Delta. In terms of naive numbers, AZ turned out the best in their comparison, but I would guess it's not statistically different from Pfizer. While they have data on Sinopharm, Pfizer, Sputnik and AZ, they only did statistical tests comparing Sinopharm and Pfizer.

They report odds ratios for various comparisons, rather than vaccine efficacy. But it's interesting to have a vaccine efficacy number for our rough comparison. In Table 4 (p11), they report that the death rates among people above 50 who are unvaccinated (37.17 per 100,000), Sinopharm vaccinated (5.45) and Pfizer vaccinated (0.96), which corresponds roughly to Sinopharm VE ~ 85%, Pfizer ~97%.
 
  • Like
  • Love
Likes Ygggdrasil and bhobba
  • #333
Oh yes. In Aus, when they talk about vaccination rates, several think tanks say the rates needed to start opening up include children under 12. No vaccine has been approved for that, but they think that is what is needed with Delta.

To me, it looks like we are going to need vaccination rates about the same as diseases such as Whooping Cough, which in Aus is about 94%. But people are slack about getting boosters when over 20 - under 20 No-Jab, No Pay applies. I had my last booster about 30 years ago. My sister got it nearly 30 years ago while pregnant - the worst time of all to get it. They were apprehensive about the effect on the baby.

Thanks
Bill
 
  • #334
atyy said:
In terms of naive numbers, AZ turned out the best in their comparison, but I would guess it's not statistically different from Pfizer.

That would be my guess as well. From UK data, both are very effective against hospitalisation and death, even against Delta.

Thanks
Bill
 
  • #335
If you have already had your 2 mRNA vaccinations, would a Delta infection be a good booster against other Covid-19 variants?

I would claim that the objective is to have a world population that is as exposed to COVID-19 as it is to (other) seasonal flu viruses - so that a COVID-19 infection is no longer an uncommonly lethal threat or one that challenges health care resources any more than the seasonal flu.

Here is my reasoning:
Given that objective, I would rather my first encounter with the actual COVID-19 be sooner rather than later for two reasons:
1) Sooner means my vaccination is still strong - and my reaction to the the virus should not be exceptionally challenging.
2) Sooner means the Delta variant, and the mRNA vaccines provide protection against that variant.

If I get Delta soon, then when something like lambda comes along, my immune system will have seen many lambda components - even though that prominent spike protein won't be one of them.

On the other had, if I dodge Delta, something like lambda could completely blind-side my immune system.
 
  • #336
.Scott said:
If you have already had your 2 mRNA vaccinations, would a Delta infection be a good booster against other Covid-19 variants?

.Scott said:
On the other had, if I dodge Delta, something like lambda could completely blind-side my immune system.
Here is a similar discussion: https://www.bbc.com/news/health-58270098. However, it is important to note that it is in the context of the UK, where vaccination and seropositivity rates are much higher than the US, whereas in the certain parts of the US, hospital systems are still under pressure, and it remains important to reduce transmission. Also, there are still deaths of fully vaccinated people who are at higher risk, so such people should continue to take the necessary precautions and a booster if their local health authority makes it available to them. In general, for an endemic virus, the idea is not to get infected deliberately, but rather to take precautions against infection (wash hands, people should not go to work when sick etc), but not to get too worried if one gets sick. Also, lambda and recent new variants are not expected to escape vaccine protection against severe disease, even if the vaccine induced neutralizing antibodies protect less against infection; this is because there are other components of the immune response that are relatively resistant to variants.
 
  • Like
  • Love
Likes Laroxe, pinball1970, bhobba and 1 other person
  • #337
.Scott said:
If I get Delta soon, then when something like lambda comes along, my immune system will have seen many lambda components - even though that prominent spike protein won't be one of them.

If you got Delta when double vaccinated, it has been shown your immunity to Covid infection is strengthened. But deliberately doing it is a risky strategy because you may, for example, have diabetes and not know it. In such a case, your chance of dying, while still much lower than not being vaccinated, has risen significantly. I have been saying throughout the pandemic that everyone should get a thorough physical, including checking vitamin D levels. That will give you a good idea of your risk, some of which you can do something about - e.g. bring vitamin D levels to what is these days considered normal. Normal has been raised a bit over recent years, but that is another story (previously 30 was considered OK - but is now mildly deficient):
https://www.racgp.org.au/afpbackissues/2008/200812/200812stroud.pdf

Thanks
Bill
 
  • Like
Likes Laroxe
  • #338
@.Scott I'd say that going out licking door knobs and randomly kissing strangers just to "unlock" next level immunity is probably a bad idea as besides Covid there are the "regular" viruses out there that everyone now seems to have forgotten about.
I think with full vaccination or previous infection (in case one has good level of antibodies) one should simply go out and live a normal life and then if one gets the virus again it's simply destiny.
I had a previous infection I am still being cautious but not to the point where I'm paranoid, stress is actually a health hazard.
 
  • Like
Likes atyy
  • #340
Ivan Seeking said:
One interesting side note I've learned in all of this: The average body temperature in the US is dropping.
https://med.stanford.edu/news/all-n...mperature-has-decreased-in-united-states.html
Yeah, I learned that when we had semi-lockdown last year. My employer instructed us to take our temperature every day. And my measurements dropped each day - so I wondered if lockdown causes temperatures to drop, and googled and found that article you linked. But when I finally started having temperatures below 35C, I thought it must be the digital thermometer. So I got a new "mercury" thermometer (no mercury, it's some other non-toxic substance), and my temperature went back up to 36.4C. :smile: The digital thermometer stopped functioning shortly after.
 
  • Informative
Likes bhobba
  • #341
atyy said:
Yeah, I learned that when we had semi-lockdown last year. My employer instructed us to take our temperature every day. And my measurements dropped each day - so I wondered if lockdown causes temperatures to drop, and googled and found that article you linked. But when I finally started having temperatures below 35C, I thought it must be the digital thermometer. So I got a new "mercury" thermometer (no mercury, it's some other non-toxic substance), and my temperature went back up to 36.4C. :smile: The digital thermometer stopped functioning shortly after.
It first came to my attention using a liquid thermometer at home for Covid. When I was a kid I was always at 98.6 unless I was sick. But now I never seem to get much above 97. At first I assumed it was the medication I'm taking. But when visiting customer sites where they take everyone's temp, I became aware of the fact that other people's temps were low too. I started asking the people taking the temps and soon it became clear that almost everyone was low! One women didn't even know that the average temp is supposed to be 98.6 because [in her words] nobody is that high.
 
  • Wow
Likes bhobba
  • #342
So you guys are saying we are cooling in the midst of global warming? I guess nature likes balance.
It's funny @Ivan Seeking but the difference between 98.6 and 97 F is about the same the global average temp has risen since industrial revolution... :biggrin:
 
  • Haha
Likes bhobba and atyy
  • #343
artis said:
So you guys are saying we are cooling in the midst of global warming? I guess nature likes balance.
It's funny @Ivan Seeking but the difference between 98.6 and 97 F is about the same the global average temp has risen since industrial revolution... :biggrin:
Haha, and here I thought global warming was due to pirates. All this time the problem has been us!

Stop climate change: Go Endothermic!

They say this in the linked reference

The researchers determined that the body temperature of men born in the early to mid-1990s is on average 1.06 F lower than that of men born in the early 1800s. Similarly, they determined that the body temperature of women born in the early to mid-1990s is on average 0.58 F lower than that of women born in the 1890s. These calculations correspond to a decrease in body temperature of 0.05 F every decade.
Of course this is getting way off topic now. But I noticed it because of Covid. A quick search revealed it's true!
 
  • #344
artis said:
@.Scott I'd say that going out licking door knobs and randomly kissing strangers just to "unlock" next level immunity is probably a bad idea as besides Covid there are the "regular" viruses out there that everyone now seems to have forgotten about.
Covid-19 is known to spread by respiration but is only presumed to spread by fomites. So licking door knobs would be unreliable at best. It's not even clear whether kissing would work. But asking them to sing for you ..
What keeps Covid from being a "regular virus" is that it is very unlike what our immune system have been trained for. The point behind catching Delta would be to relegate it to the status of a "regular virus".

artis said:
I think with full vaccination or previous infection (in case one has good level of antibodies) one should simply go out and live a normal life and then if one gets the virus again it's simply destiny.
I had a previous infection I am still being cautious but not to the point where I'm paranoid, stress is actually a health hazard.
"If you don't do the choosing, life will choose for you, and it may not be the choice you want". - Robert N. Anthony
 
Last edited:
  • Like
Likes Evo and bhobba
  • #345
bhobba said:
If you got Delta when double vaccinated, it has been shown your immunity to Covid infection is strengthened. But deliberately doing it is a risky strategy because you may, for example, have diabetes and not know it. In such a case, your chance of dying, while still much lower than not being vaccinated, has risen significantly.
I believe your Math is incomplete. You are comparing a 100% chance of getting Delta while recently vaccinated against an unspecified chance of getting any variant at any time.

I was actually going to try to list off the decision-making Math here - but it gets pretty complicated pretty fast. For examples: You would need to model your vaccination effectiveness, cross-variant immunity effectiveness, and risk of infection as functions of time. And there is value in delaying the inevitable.

You say I might have a risk factor and not know it. But if I don't know it, how much incentive will I have over the next several years to avoid COVID-19 - or any other infection I may be vulnerable to. Given that situation, it might still be better to get it now. If the lethality now versus later is 0.4 vs. 0.9, better to get it now. If it's 0.94 vs. 0.99, better to delay as long as possible. Of course, that doesn't factor in one's personal value of time. If you only want to make it to the end of this year to complete your bucket list, then avoid COVID.

A major factor is the likelihood of avoiding COVID completely. If you know you are at very high risk even when vaccinated, then this is the option for you.

And until recently, is was the strategy for Australians as well. Delta has made that strategy very difficult.

Besides, my HbA1c is 4.9.
 
  • #346
atyy said:
Here is a similar discussion: https://www.bbc.com/news/health-58270098. However, it is important to note that it is in the context of the UK, where vaccination and seropositivity rates are much higher than the US, whereas in the certain parts of the US, hospital systems are still under pressure, and it remains important to reduce transmission.
In New England, the vaccination rate is roughly 70% and hospitals are not overly strained by COVID.
This is in great contrast to south-eastern US.
atyy said:
Also, there are still deaths of fully vaccinated people who are at higher risk, so such people should continue to take the necessary precautions and a booster if their local health authority makes it available to them.
People at very high risk need to take exceptional measures to avoid Delta. If society decides to assist them at the "endemic" level (not just their personal quarantine level), then we would need to talk about how to very reliably eliminate Delta ASAP - for example by rapidly spreading the infection while the vulnerable are isolated. I would not recommend that.

atyy said:
In general, for an endemic virus, the idea is not to get infected deliberately, but rather to take precautions against infection (wash hands, people should not go to work when sick etc), but not to get too worried if one gets sick.
But this is not the general case. We have a situation where most of the population has a very low "breadth" (to use the term from the article you cited) of immunization - limited to just one protein.
atyy said:
Also, lambda and recent new variants are not expected to escape vaccine protection against severe disease, even if the vaccine induced neutralizing antibodies protect less against infection; this is because there are other components of the immune response that are relatively resistant to variants.
They won't escape once the "breadth" issue has been addressed - through infection or through a different vaccine.

Yes, there are two or three immune system mechanisms that respond to the vaccination - antibodies, T-Cells, and perhaps other lymphocytes. But with the mRNA vaccinations only, all of them are unvaccinated for any future variant with an unrecognized spike protein.
 
  • #347
.Scott said:
But this is not the general case. We have a situation where most of the population has a very low "breadth" (to use the term from the article you cited) of immunization - limited to just one protein.
It is true that immunization with more antigens could be beneficial in the longer term, but even the one protein used for immunization (in the current Pfizer vaccine) corresponds to many epitopes, and memory B and T cells have the ability to recognize variants. This is likely why protection against severe disease caused by variants has remained either unchanged or fallen much less compared to the decreased protection against infection.
 
Last edited:
  • Like
Likes Evo and Laroxe
  • #348
.Scott said:
A major factor is the likelihood of avoiding COVID completely. If you know you are at very high risk even when vaccinated, then this is the option for you. And until recently, is was the strategy for Australians as well. Delta has made that strategy very difficult.
Glug glug for Aussies - and don't I know it. It's fine right now in Brisbane, where I live, but it will not last - it is just a matter of time.

The strategy now in NSW and Victoria, where it is out of control with an R of about 1.3 (the highest of just about any other country), is to get vaccinated, vaccinate and vaccinate some more. They have achieved over 70% first doses in NSW and soon will be 80% and hopefully higher. It is expected over 80% two doses by November. That must bring R down - with 70% and just 1 dose at 30% efficiency, my calculation shows it will be below 1 and getting better as more get second doses, and first doses rise above 80%. I am hopeful it soon will be under control here in Aus. But people need to wake up. Queensland only has 53% first doses, and my sister is only getting vaccinated reluctantly. I try to explain the importance, but she says, what do you know.

Immunologists are divided on if we can eradicate it. My calculations indicate 95% vaccination and a third dose could do it - but that is a tough target. Most believe we will have to live with it but take precautions. I wish we would look more at Taiwan, which already has R below 1 and starting from virtually zero is immunising fast - so fast it approved its own homegrown vaccine (Medigen - 600,000 doses administered in a week alone) before stage 3 trials were completed:
https://thediplomat.com/2021/07/why-taiwan-is-beating-covid-19-again/

10 million first doses already - waiting for first doses to be completed before concentrating on second doses. Australia could learn a thing or two from that.

Thanks
Bill
 
Last edited:
  • Like
Likes .Scott
  • #349
bhobba said:
Immunologists are divided on if we can eradicate it. My calculations indicate 95% vaccination and a third dose could do it - but that is a tough target. Most believe we will have to live with it but take precautions.
For eradication, one also has to take into account that protection from infection declines over time due to falling antibody levels and viral mutations. It seems that protection from severe disease is quite steady despite that, so I'm in the live with it camp. I think that if the vaccination rate approaches 100% in vulnerable groups, that the precautions we take might not have to be much more than for flu.

Rather amazingly, Portugal is reporting that 99% of people aged above 65 have been fully vaccinated (both doses)!
https://covid19.min-saude.pt/wp-content/uploads/2021/09/Relato%CC%81rio-de-Vacinac%CC%A7a%CC%83o-n.o-29.pdf
 
  • Like
  • Love
Likes Evo, Laroxe, Astronuc and 1 other person
  • #350


a rather reasonable assessment of the latest situation
 
  • Like
Likes .Scott and bhobba

Similar threads

  • Biology and Medical
17
Replies
562
Views
26K
  • Biology and Medical
Replies
22
Views
2K
Replies
1
Views
757
  • Biology and Medical
Replies
1
Views
942
  • Biology and Medical
2
Replies
42
Views
4K
Replies
3
Views
2K
  • Biology and Medical
Replies
4
Views
2K
  • Biology and Medical
Replies
3
Views
1K
  • Biology and Medical
6
Replies
179
Views
13K
Replies
2
Views
965
Back
Top